Kornimate/medical-research-clean huggingface dataset:
study of motor slowing in parkinson's disease by a computerized mental chronometry paradigm

Conditions: Parkinson Disease; Huntington Disease

Summary: action slowing has been demonstrated in many diseases. parkinson's disease (pd) and huntington's disease (hd) are two neurodegenerative diseases affecting the basal ganglia, particularly the medial globus pallidus, and the clinical expression of these two diseases is characterized by a combination of motor and cognitive disorders, but with two opposing patterns of dysfunction. action slowing has been demonstrated in both of these diseases and has been extensively studied in parkinson's disease, suggesting a perceptive-cognitive origin. far fewer studies have been conducted in huntington's disease. however, all of these studies were performed with different methodologies in small cohorts and the value of the proposed study is to use a validated and standardized computerized mental chronometry paradigm, providing a better understanding of the mechanisms of action slowing in these two diseases and to more clearly define a disease-specific profile.


Eligibility criteria:
inclusion criteria: * agreeing to participate in the study * french mother tongue * mmse \> 20/30 * specific to the mp and mh: * parkinson's disease: * defined by the criteria of the ukpdsbb * stage 1 , 2 or 3 hoehn and yahr (on) * age of onset of the disease known * brain mri performed during follow-up * huntington disease : * genetically defined (cag \> 35) * weaning neuroleptic ( tercian® and solian® : 2 days; haldol® : 5 days ; tiapridal® and xenazine : 1 day ; zyprexa® : 4 days) * early stage : fahn and shoulson i and ii is a cft score between 7 and 13 exclusion criteria: * illiteracy, writing or reading difficulties * visual perceptual auditory deficit or preventing reading, drawing, writing or understanding instructions * visual hallucinations * significant history may sound on cognition (unbalanced thyroid dysfunction, ischemic heart disease or embolic unstabilized or symptomatic, progressive neoplasia, chronic alcoholism weaned or not) * current or previous neurological diseases other than mh or mp: ischemic cerebral vascular accident or bleeding, head injuries (loss of higher knowledge in 15 minutes), epilepsy requiring treatment. * psychiatric disorders depression unless treated (stable treatment for 1 month) * psychotropic treatment (except anxiolytic, antidepressant steady since 1 month) * inability to achieve an autonomous operation without technical assistance over a distance of 20 meters. * inability to stand without technical assistance for 30 seconds.

Keywords: motor slowing computerized mental chronometry paradigm
assessment of serum fam19a5 level in egyptian patients with neuromyelitis optica spectrum disorder

Conditions: Assessment of Serum FAM19A5level in Egyptian Patients With NMOSD

Summary: neuromyelitis optica spectrum disorders (nmosd) are severe inflammatory autoimmune conditions of the central nervous system (cns) . the discovery of nmosd-specific aquaporin 4 (aqp4) antibody has established that nmosd is indeed a distinct entity . approximately 80% of patients with nmosd test positive for aquaporin-4 (aqp4) immunoglobulin g (igg) antibodies .aqp4-igg associated nmosd appears to target astrocytes, not myelin, leading to elevated markers of astrocyte injury during attacks . untill now there is limited research about understanding the biomarkers of astrocyte injury and the following reactive gliosis. family with sequence similarity 19-membera5 (fam19a5) protein is postulated to regulate nervous and immune cells of the brain as a brain-specific chemokine, but its precise functional role is not well understood . a recent study suggested that fam19a5 is secreted by reactive astrocytes following cns damage and triggers reactive gliosis . in another recent study, serum fam19a5 was higher in patients with nmosd-aqp4 than in other cns demyelinating diseases and healthy controls . so, we need to study the level of this novel biomarker among our egyptian nmosd patients and whether it shall be a new biomarker for nmosd . moreover just few studies conducted on cognitive dysfunctions in nmosd patients and they demonstrate a significant decrease of cognitive abilities and the prevalence of ci in different samples varies between 30 and 70% .so further studies are needed to investigate the cognitive performance in nmosd patients

sixty patients diagnosed as nmosd based on the recently revised 2015 international consensus diagnostic criteria for nmosd ,attending neurology clinic, asyut university hospitals, asyut university and kasr al-ainy multiple sclerosis/neuroimmunology clinic, cairo university hospitals, cairo university, egypt, through one and half year from study onset. sixty healthy volunteers, without any neurological or systemic medical diseases, age and sex matched , will be enrolled as healthy controls(hcs). aim of the work : 1. determining the serum level of fam19a5 in a cohort of egyptian patients with nmosd in comparison with healthy controls and its relationship with the different clinical phenotypes and parameters and disease severity of nmosd patients. 2. cognitive performance of nmosd patients in comparison with healthy controls.

Eligibility criteria:
inclusion criteria: * 1-both nmosd aqp-4 +ve and aqp-4 -ve. 2-age \ 60 years. 3-both males and females. 4-both receiving or not receiving current immunosuppressants. 5-any score of extended disability status scale (edss). exclusion criteria: * 1-any neuropsychiatric disorder other than nmosd such as multiple sclerosis ,cns infectious diseases or malignancy. 2-systemic conditions influencing analysis of clinical and serological data , such as general infection, malignancy, and hematologic diseases. 3-illiterate patients. 4-history of drug or alcohol abuse
dietary supplement for the prevention of cognitive decline in a very elderly population.

Conditions: Mild Cognitive Impairment

Summary: the purpose of this study is to determine whether an omega-3 fatty acid supplementation is effective in the prevention of progressive cognitive decline in elderly people aged 75 years or older.

participants are residents at three nursing homes in pamplona (spain). we assumed that 20% of elderly people have a cognitive decline and we estimated a 5% of cognitive decline in the intervention group. sample size estimated was 85 participants for each arm, assuming two groups with an alpha of 0.05, 80% power and accounting for 10% of participants lost to follow-up. repeated measures anova, cox regression and multiple linear regression analysis will be used for the statistical analysis of data.

Eligibility criteria:
inclusion criteria: * elderly people aged 75 years or older * global deterioration scale \< 4 * capacity to complete the tests exclusion criteria: * neurological, physical or psychiatry conditions, obtained from the medical history, that may have an influence on the cognitive function. * dementia * history of epilepsy, convulsions
acoustic cardiographic assessment of heart function in comparison to doppler-echocardiography

Conditions: Heart Failure, Congestive; Antineoplastic Agents

Summary: in this study, the investigators sought to determine whether an acoustic cardiographic assessment of heart function is equivalent to doppler-echocardiography in patients who are treated with cardio-toxic cytostatic agents.

patients receiving cardio-toxic cytostatic agents are examined by doppler-echocardiography and acoustic cardiography before, during, and after the cytostatic treatment. doppler-echocardiography measures ejection fraction, tdi, speckle tracking, and further parameters. acoustic cardiography (audicor, inovise medical inc., portland, usa) simultaneously integrates heart sounds and single-channel electrocardiography input to generate multiple parameters that correlate to established hemodynamic measures. heart function as assessed by doppler-echocardiography is then compared to the heart function as assessed by audicor ecg.

Eligibility criteria:
inclusion criteria: * patients with malignant disease with scheduled anthracycline and trastuzumab therapy
broccoli sprout intervention in qidong, p.r. china

Conditions: Environmental Carcinogenesis

Summary: this study is a 12 week placebo-controlled phase ii broccoli sprout intervention to be conducted in qidong, p.r. china. one thousand two hundred people from the farming townships will be screened and three hundred eligible individuals will be enrolled in the study. participants will be randomized into two treatment groups: one will receive a juice beverage containing glucoraphanin- and sulforaphane-rich broccoli sprout extract, pineapple juice, lime juice, and water and the other will receive a placebo beverage containing pineapple juice, lime juice and water. participants will drink their assigned beverage every evening and provide biweekly urine samples and monthly blood samples. the principal endpoints of this study are pharmacokinetic evaluation of elimination of glucoraphanin/sulforaphane and their metabolites in urine and pharmacodynamic evaluation through measures of urinary levels of exposure biomarkers for dietary and air-borne toxins, which are known to be high in this population.


Eligibility criteria:
inclusion criteria: * age 21-65 years * in good general health with no history of chronic illness * normal liver function tests: alanine aminotransferase (alt), aspartate aminotransferase (ast), bilirubin) * normal renal function tests (creatinine, blood urea nitrogen, urinalysis) * serum alpha-fetoprotein negative exclusion criteria: * personal history of cancer except for non-melanoma skin cancer * use of prescribed medications * hepatomegaly by clinical exam * for women, a positive pregnancy test

Keywords: glucoraphanin sulforaphane pharmacokinetics pharmacodynamics broccoli sprout carcinogens, environment
treatment of renal colic in the emergency department: comparison between magnesium sulfate and lidocaine.

Conditions: Renal Colic

Summary: rate of intravenous magnesium sulfate vs lidocaine to treat renal colic in the emergency department.

magnesium sulfate (mgso4) is a n-methyl-d-aspartate (nmda) receptor antagonist and is thought to be involved in the modulation of pain. there has been little direct evidence that mgso4 relieve neuropathic pain and prevents opioid-induced hyperalgesia in humans. intramuscular diclofenac seems to offer the most effective sustained analgesia for renal colic in the ed and has few side effects. lidocain became the agent of choice in visceral and central pain. intravenous lidocain is effective in the management of neuropathic pain such as diabetic neuropathy, post-surgical pain, post-herpetic pain, headaches and neurological malignancies. at low doses, lidocain is known as a relatively safe medication. lidocain seems an effective treatment who can be administrated in the renal colic. objective of study: evaluate the analgesic effect of a standard dose of intravenous magnesium added to intramuscular diclofenac compared to intravenous lidocain combined to intramuscular diclofenac or intramuscular diclofenac alone in patients presenting to the ed with renal colic and whether it can reduce opioid consumption.

Eligibility criteria:
inclusion criteria: * informed consent. * age between 18 and 65 years . * diagnosis of renal colic made by an emergency medicine physician, based on history and clinical findings, and urine analysis or by identifying the urinary tract stone using ultrasonography or radiologic imaging including ct scan .-with moderate to severe pain (visual analogic scale ≥5 ). exclusion criteria: * known renal or hepatic dysfunction, use of nsaids and/or opioids within 6 h before presentation * history of bleeding diathesis, history of peptic ulcer disease or gastrointestinal hemorrhage, * history of cardiac arrhythmia, severe coronary artery disease, seizures, presence of any peritoneal sign, altered mental status, and anticoagulant medication or coagulation disorders. * use of any analgesics or spasmolytics in the previous 4 hours before admission, hemodynamic instability, and prior known allergy to lidocaine or morphine . * pregnant women , breast feeding * allergy or contraindications to nsaids, lidocaine or mgso 4

Keywords: acute pain renal colic magnesium sulfate lidocain diclofenac
effect of short-term oxygen during cpet in guch

Conditions: Grown-up Congenital Heart Disease (GUCH)

Summary: in a randomized, sham-controlled crossover trial the investigators will test whether supplemental oxygen given during cardiopulmonary exercise testing will improve exercise performance and physiological parameters in patients with grown-up congenital heart disease.


Eligibility criteria:
inclusion criteria: * guch, stable medication for at least 4 weeks. exclusion criteria: * instable status, pregnancy, clinically relevant concomitant diseases, inability to follow the study procedures
effects of digivibe on pain in subjects undergoing intramuscular injections, subcutaneous injections, and fingersticks

Conditions: Healthy

Summary: this is a single-center, unblinded, prospective, cross-over study. the study population will include twenty (n=20) healthy subjects (10 men and 10 women) over the age of 18 with a self-reported fear/dislike of needles. subjects who qualify for the study based on the study inclusion and exclusion criteria and who consent to participate in the study will undergo two (2) intramuscular (im) injections in the deltoid muscle, two (2) subcutaneous (sc) injections in the abdomen, and two (2) fingersticks with a lancing device in the middle finger. one injection in each location will be performed using with no intervention (as per standard of care) and the other injection in each location will be performed using the digivibe device.

while the complete mechanisms of pain and pain diversion are not completely understood, digivibe locally targets the skin's pain receptors. therefore, it is proposed that the vibrations from the digivibe device will counteract and/or lessen the pain around the injection site. this study will determine whether the use of digivibe during a procedure requiring injections provides greater reduction in pain than injections with no intervention (standard of care). this information will aid healthcare providers in selecting the best approach to management of pain in patients who must undergo injections that could cause pain and may benefit from additional pain reduction.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years 2. bmi 18.5-29.9 kg/m2 (normal) 3. self-reported fear/dislike of needles exclusion criteria: 1. chronic (daily) use of nonsteroidal anti-inflammatory drugs (nsaids) (i.e. ibuprofen, aspirin, naproxen, etc.), antiplatelet medications (i.e. clopidogrel, prasugrel, ticagrelor, cangrelor, cilostazol, etc), or anticoagulant medications (i.e. warfarin, dabigatran, rivaroxaban, apixaban, edoxaban, heparin, enoxaparin, fondaparinux, etc.) * note: nsaids used as needed are not excluded as long as they are not used within 3 days of study screening and enrollment 2. chronic (daily) use of analgesics (i.e. acetaminophen, nsaids \[ie. ibuprofen, naproxen\], opioids \[ie. morphine, oxycodone, fentanyl\], lidocaine, cannabinoids \[ie. cbd, thc\],) * note: analgesics used as needed are not excluded as long as they are not used within 3 days of study screening and enrollment 3. any condition in the opinion of the study investigator that would potentially confound the results of this study

Keywords: digivibe vibration anesthesia
pet tdm fdg-choline as a decision-making tool for routine care on the liver transplant list for hcc

Conditions: Hepatocellular Carcinoma; Liver Transplant

Summary: hcc is the most common malignant liver tumor for which liver transplantation is one of the pivotal curative treatments. the best possible selection of patients who are candidates for transplantation is essential in the current context of a shortage of transplants. performing a pet ct scan is not currently recommended in the pre-liver transplant workup for hcc. however, pet ct using in a complementary manner the fdg and choline tracers appears promising in the management of hcc in view of its wide use in oncology and its major diagnostic and prognostic contribution compared to conventional imaging. in order to address this issue, a prospective cohort study including patients from the university hospital of rouen and lille with hepatocellular carcinoma meeting the criteria for indication of liver transplantation validated in spc will be set up, the main objective of which will be to assess the decision-making contribution of pet tdm fdg and choline in addition to conventional imaging in the pre-transplant assessment.


Eligibility criteria:
inclusion criteria: * patient candidate for liver transplantation for hepatocellular carcinoma from the university hospital of lille and rouen, whose therapeutic transplantation project has been validated and having an afp score ≤ 2 (diagnosis of hcc defined on non-invasive imaging criteria according to the recommendations of easl-eortc 2012 or confirmed histologically). * no opposition to participating in the study. * patient affiliated to a social security scheme exclusion criteria: * patient with an afp score ≥ 3 * patient contraindicated to pet fdg or choline. * other tumor: cholangiocarcinoma. * diabetes unbalanced hba1c\> 9%, and fasting hyperglycemia (\> 2g / l) which does not allow the completion of the pet examination. * patient under guardianship or curatorship. * pregnant or breastfeeding woman.

Keywords: hepatocellular carcinoma liver transplantation pet ct, fluorodeoxyglucose fluorodeoxyglucose choline
oblique subcostal transversus abdominis plane block versus transmuscular quadratus lumborum block for pain management in laparoscopic gynecological surgery

Conditions: Postoperative Pain; Surgery

Summary: laparoscopic gynecological surgery causes postoperative pain.the primary objective of this study is to compare the effect of ultrasound (us)-guided oblique subcostal transversus abdominis plane block (ostap) on 24-hour total analgesic consumption with transmuscular quadratus lumborum block (tqlb).

patients between the ages of 18-65, who will undergo laparoscopic gynecological surgery, american society of anesthesiologists (asa) class i-ii-iii, body mass index (bmi) in the range of 18-25 kg/m², and who will use 3 or 4 trocar for surgery will be included in the study. patients will be randomized into two groups. ostap block will be performed for ostapb group and tql block will be performed for tqlb group. patients will be administered postoperative 4x500 mg iv paracetamol as needed (if visual analogue scale (vas) score is 4 or higher). if the vas score remains at 4 or higher 30 minutes after paracetamol administration, 1 mg/kg iv tramadol will be administered as a rescue analgesic (with a daily maximum dose of 400 mg). the primary outcome is to compare the total analgesic consumption within the first 24 hours after surgery. the secondary outcome is to compare the time to the first postoperative analgesic requirement, vas scores at rest and on movement, and assess the impact of these two blocks on the quality of recovery using the qor-15 scale

Eligibility criteria:
inclusion criteria: * ages of 18-65 * patients who will undergo laparoscopic gynecological surgery * asa i-ii-iii patients * body mass index (bmi) in the range of 18-25 kg/m² * patients who will undergo surgery using 3 or 4 trocars exclusion criteria: * asa iv-v * patients with a known or suspected allergy to local anesthetics * coagulopathy * injection site infection * severe neurological or psychiatric disorders * severe cardiovascular disease * liver failure * kidney failure (glomerular filtration rate \<15 ml/min/m²) * chronic opioid use (\>6 months) * surgical durations less than 45 minutes or greater than 120 minutes

Keywords: postoperative pain pain management oblique subcostal transversus abdominis plane block transmuscular quadratus lumborum block quality of recovery
comparing effects of whole body vibration and resisted training on quadriceps strength after lower limb burns

Conditions: Lower Limb Burn; Muscle Weakness Condition

Summary: evaluate the therapeutic effect of whole body vibration and resistance training on strength of quadriceps post lower limb burn

study design: this randomized controlled trial will include 60 patients suffering from partial thickness burns. the patients will be randomly divided into two equal groups, with each group consisting of 30 patients. study explanation: a verbal explanation about the importance of the study, its procedures, main aims, and conceptual approach will be provided to every patient. study procedures: the procedures of this study will be divided into two main categories: evaluation procedures and treatment procedures. evaluation procedures: evaluation will be conducted using isokinetic dynamometry for all patients both before and after the study. treatment procedures: first group: patients in the first group will receive whole body vibration therapy. second group: patients in the second group will undergo resisted exercises.

Eligibility criteria:
inclusion criteria: the subject selection will be according to the following criteria: * age range between 25-40 years. * male and female patients will participate in the study. * all patients have burn of 30% to 40%. * all patients have burn at lower limb * all patients have second degree burn * all patients have no chronic diseases. * all patients enrolled to the study will have their informed consent exclusion criteria: the potential participants will be excluded if they meet one of the following criteria: * prosthesis; * any neurological, musculoskeletal,or other chronic disease * participation in an outside resistance training programs * recent fracture or bone injury * any medication that could affect strength adaptations and adversely affect the results of the study * previous brain injury * any disease affecting balance, vestibular or visual disorders * history of epilepsy. * cardiac diseases. * burn of sole of foot. * exposed foot tendons. * severe osteopathy. * marked anemia (ht\<25%). * serious peripheral vessel disease * acute medical problem at study onset.

Keywords: burn whole body vibration resisted exercise isokinetic
clinical trial evaluating safety and efficacy of resomelagon on dengue infection (resovir-2)

Conditions: Dengue Fever

Summary: the goal of this clinical trial is to understand if resomelagon can treat adult patients with dengue virus infection. the main questions the investigators aim to answer are: is resomelagon safe to use in patients with dengue? is resomelagon able to reduce the duration of illness? (defined by clinical and laboratory criteria) participants will be allocated to resomelagon or placebo groups in this study and asked to take the medication and submitted to blood tests.


Eligibility criteria:
inclusion criteria: * patients who are 18 to 65 years old; * able to understand study procedures and give informed consent; * presents with more than 36 and less than 84h since symptoms onset; * symptoms compatible with dengue infection (fever, myalgia, arthralgia, headache or conjunctivitis) with positive antigen test or polymerase chain reaction test. exclusion criteria: * has any comorbidity which is perceived as significant by the investigator; * significant laboratory abnormalities discovered at triage: hemoglobin \ 3x upper limit of normal; total bilirubin \>1,5 x upper limit of normal; glomerular filtration rate \< 60mls/min/1,73m2; * contraindications or known hypersensitivity to resomelagon; * presents as dengue with warning signs or severe dengue at inclusion; * currently participating in another drug clinical trial; * clinical evidence of another infection that might explain current symptoms; * pregnant women or women actively trying to achieve pregnancy.

Keywords: resomelagon resolution of inflammation melanocortin dengue resovir-2